Gilead Sciences Inc (GILD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gilead Sciences Inc (GILD) has a cash flow conversion efficiency ratio of 0.147x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.33 Billion) by net assets ($22.62 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Gilead Sciences Inc stock valuation for the company's overall valuation and market capitalisation.
Gilead Sciences Inc - Cash Flow Conversion Efficiency Trend (1990–2024)
This chart illustrates how Gilead Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gilead Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gilead Sciences Inc ranked by their cash flow conversion efficiency. Explore GILD cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IND.D.D.TEXT.UNSP.ADR 1/2
F:IXD2
|
N/A |
|
PepsiCo Inc
NASDAQ:PEP
|
0.104x |
|
Toyota Motor Corporation
F:TOM
|
0.021x |
|
Banco Santander S.A.
MC:SAN
|
-0.005x |
|
Walt Disney Company
NYSE:DIS
|
0.060x |
|
Reliance Industries Limited
NSE:RELIANCE
|
0.094x |
|
Foxconn Industrial Internet Co Ltd
SHG:601138
|
0.052x |
|
Toyota Motor Corporation
F:TOMA
|
0.021x |
Annual Cash Flow Conversion Efficiency for Gilead Sciences Inc (1990–2024)
The table below shows the annual cash flow conversion efficiency of Gilead Sciences Inc from 1990 to 2024. View Gilead Sciences Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $19.25 Billion | $10.83 Billion | 0.563x | +59.87% |
| 2023-12-31 | $22.75 Billion | $8.01 Billion | 0.352x | -17.72% |
| 2022-12-31 | $21.21 Billion | $9.07 Billion | 0.428x | -20.85% |
| 2021-12-31 | $21.06 Billion | $11.38 Billion | 0.540x | +20.56% |
| 2020-12-31 | $18.22 Billion | $8.17 Billion | 0.448x | +11.04% |
| 2019-12-31 | $22.65 Billion | $9.14 Billion | 0.404x | +3.49% |
| 2018-12-31 | $21.53 Billion | $8.40 Billion | 0.390x | -32.79% |
| 2017-12-31 | $20.50 Billion | $11.90 Billion | 0.580x | -34.08% |
| 2016-12-31 | $19.36 Billion | $17.05 Billion | 0.880x | -20.81% |
| 2015-12-31 | $19.11 Billion | $21.25 Billion | 1.112x | +37.21% |
| 2014-12-31 | $15.82 Billion | $12.82 Billion | 0.810x | +206.50% |
| 2013-12-31 | $11.74 Billion | $3.10 Billion | 0.264x | -21.03% |
| 2012-12-31 | $9.54 Billion | $3.19 Billion | 0.335x | -36.82% |
| 2011-12-31 | $6.87 Billion | $3.64 Billion | 0.530x | +14.47% |
| 2010-12-31 | $6.12 Billion | $2.83 Billion | 0.463x | -2.23% |
| 2009-12-31 | $6.51 Billion | $3.08 Billion | 0.473x | -1.35% |
| 2008-12-31 | $4.47 Billion | $2.14 Billion | 0.480x | -2.11% |
| 2007-12-31 | $3.60 Billion | $1.77 Billion | 0.490x | -24.77% |
| 2006-12-31 | $1.87 Billion | $1.22 Billion | 0.652x | +179.67% |
| 2005-12-31 | $3.03 Billion | $705.64 Million | 0.233x | -14.16% |
| 2004-12-31 | $1.87 Billion | $507.96 Million | 0.272x | +16.07% |
| 2003-12-31 | $1.00 Billion | $234.61 Million | 0.234x | +79.61% |
| 2002-12-31 | $571.34 Million | $74.41 Million | 0.130x | +146.40% |
| 2001-12-31 | $452.44 Million | $-126.98 Million | -0.281x | -157.96% |
| 2000-12-31 | $351.12 Million | $-38.20 Million | -0.109x | +48.33% |
| 1999-12-31 | $297.29 Million | $-62.60 Million | -0.211x | -36.97% |
| 1998-12-31 | $333.70 Million | $-51.30 Million | -0.154x | +10.50% |
| 1997-12-31 | $317.30 Million | $-54.50 Million | -0.172x | -203.65% |
| 1996-12-31 | $291.70 Million | $-16.50 Million | -0.057x | +62.74% |
| 1995-12-31 | $151.50 Million | $-23.00 Million | -0.152x | +52.29% |
| 1994-12-31 | $86.10 Million | $-27.40 Million | -0.318x | -63.81% |
| 1993-12-31 | $115.30 Million | $-22.40 Million | -0.194x | -204.29% |
| 1992-12-31 | $139.40 Million | $-8.90 Million | -0.064x | -82.22% |
| 1991-12-31 | $105.60 Million | $-3.70 Million | -0.035x | +85.11% |
| 1990-12-31 | $10.20 Million | $-2.40 Million | -0.235x | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the t… Read more